Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

iming and scope of clinical trials of NGX267. Such statements are subject to numerous risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether the results of completed trials of NGX267 are predictive of results in subsequent trials of such product candidate; whether further testing of NGX267 will result in data sufficient to support regulatory approval; whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether the company will be able to develop and obtain regulatory approval of its product candidates for treatment of multiple diseases and disorders; whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its product candidates will support a filing for marketing approval, will be approved by applicable regulatory authorities, or if approved, will prove competitive in the market; and whether the necessary financing to support its product development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics ann
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. ... pivotal TELESTAR Phase 3 clinical trial met its ... etiprate in treating cancer patients with carcinoid syndrome ... standard of care. Telotristat etiprate was discovered using ... and is the company,s first discovery to complete ...
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is ... (FDA) issued a warning letter to C.R. Bard, the manufacturer ... taking adequate strides to correct violations the agency found at ... these violations after the FDA cited them during Inspectional Observations ... in Bard,s Tempe, AZ , location and ...
(Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
(Date:8/3/2015)... , ... August 03, 2015 , ... ... brokerage firm, announced today that Joe Williams has joined its growing California employee ... delivering HUB's differentiated service model to his clients. Mr. Williams will be joining ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... ... 03, 2015 , ... Career Step, an online institution offering ... for Healthcare Documentation Integrity’s (AHDI) conference being held in Alexandria, Virginia, on Friday ... AHDI conference provides us to interact with those in the healthcare documentation industry,” ...
(Date:8/2/2015)... (PRWEB) , ... August 02, 2015 , ... Molecular biologists ... powerful prognostic indicator for mesothelioma. Surviving Mesothelioma has just posted an article on the ... University of New South Wales tested for Ki67 expression in tissue samples from 42 ...
(Date:8/1/2015)... ... 2015 , ... Have you ever wondered what “Karma” really means? Does it even exist? Can ... , Vedic tradition, which gave birth to Hinduism, is one of the most ancient spiritual ... this tradition. According to the wisdom of this heritage, Karma is a very real and ...
Breaking Medicine News(10 mins):Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2
... ... with Alzheimer,s disease and disabilities, and a decreasing work force to care for them, threatens ... care business owner. , ... NE (PRWEB) September 29, 2009 -- A crisis in aging, fueled by increasing numbers of ...
... ... foot and ankle Pain." Claims Dr. Katz , ... Tampa, FL (PRWEB) September 29, 2009 -- Foot pain and foot ... of solutions for their foot and ankle pain and are growing frustrated with continuous visits ...
... study by researchers at The George Institute for International Health ... to PCPs with acute lower back pain to have previously ... documented was vertebral fracture, with half of the cases identified ... in the October issue of Arthritis & Rheumatism , ...
... shoe choices early in life suffer with foot pain in later ... foot pain as women, due to type of shoes they wear. ... Arthritis Care & Research , a journal published by Wiley-Blackwell ... reveal that foot and toe symptoms are among the top 20 ...
... cancer with the Prostate Specific Antigen (PSA) test in ... becomes symptomatic, knowing whether screening is beneficial for these ... or no reductions in prostate cancer mortality among those ... against the more common and immediate downsides of increasing ...
... at Harbor-UCLA Medical Center (LA BioMed) will honor Los Angeles ... founder and president of Kakkis EveryLife Foundation, as its "Spirit ... 6 at the Terranea Resort in Rancho Palos Verdes. ... for the excellence each represents in his chosen field," said ...
Cached Medicine News:Health News:Crisis in Aging: Disability and Alzheimer's: Lack of Caregivers Threatens South Florida Seniors' Ability to Stay Home 2Health News:Crisis in Aging: Disability and Alzheimer's: Lack of Caregivers Threatens South Florida Seniors' Ability to Stay Home 3Health News:Crisis in Aging: Disability and Alzheimer's: Lack of Caregivers Threatens South Florida Seniors' Ability to Stay Home 4Health News:Dr. Marc Katz, Leading Podiatric Surgeon Adds High Powered Color Ultrasound To Cryosurgery Procedures and Treatments 2Health News:PCPs are front line defense in diagnosing serious illness in patients with acute lower back pain 2Health News:Women who make poor shoe choices at risk for foot pain later in life 2Health News:UNC expert: Better decision support tools needed for prostate cancer screening choice 2Health News:LA BioMed to honor Emil D. Kakkis, M.D., Ph.D., and LA County Supervisor Don Knabe 2
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
... to dry trays to specialty vaginal & ... Health offers the widest offering in patient ... that are proven to be safe and ... surgical site infections. Cardinal Health Scrub Care ...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... The Anti-HTLV Mixed Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by manufacturers and ... assays. Comprehensive data from all major test ...
Medicine Products: